Axovant Announces Upcoming Presentations at the Annual Meeting of the American Society of Gene and Cell Therapy

-Details from ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD and the AXO-AAV-GM2 program to be featured in oral presentations-

-Preclinical data from AXO-AAV-GM1 program to be highlighted in poster presentation-

BASEL, Switzerland, April 16, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, announced two upcoming oral presentations and one poster presentation at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT). Details from the ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD for the treatment of Parkinson’s disease and the delivery approach for the AXO-AAV-GM2 program will be shared in oral presentations. Additionally, preclinical data related to the AXO-AAV-GM1 program will be presented in a poster.

Details of the oral presentations are as follows:

Title: A Safe and Reliable Technique for Central Nervous System Delivery of AAV Vectors via the Cisterna Magna (Abstract #31)

Session date/time: April 29, 2019, 10:30-10:45am ET

Title: AXO-LENTI-PD: a second-generation lentiviral gene therapy for the treatment of Parkinson’s Disease (Abstract #222)

Session date/time: April 30, 2019, 3:30-3:45pm ET

Details of the poster presentation are as follows:

Title: Intravenous Delivery of AAV Gene Therapy in GM1 Gangliosidosis (Abstract #401)

Session date/time: April 30, 2019, 5:00pm ET

The ASGCT Annual Meeting will be held in Washington, DC, April 29 - May 2, 2019. Additional information on the meeting can be found on the ASGCT website:

About Axovant Gene Therapies

Axovant, part of the Roivant family of companies, is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurological and neuromuscular diseases. The company’s current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis (including Tay-Sachs disease and Sandhoff disease), Parkinson’s disease, oculopharyngeal muscular dystrophy (OPMD), amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. Axovant is focused on accelerating product candidates into and through clinical trials with a team of experts in gene therapy development and through external partnerships with leading gene therapy organizations. For more information, visit

About Roivant

Roivant Sciences aims to improve health by rapidly delivering innovative medicines and technologies to patients. It does this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology to drive greater efficiency in R&D and commercialization. For more information, please visit

Forward Looking Statements and Information

Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as “may,” “might,” “will,” “expect,” “plan,” and other similar expressions are intended to identify forward-looking statements. All forward-looking statements are based on estimates and assumptions by Axovant’s management that, although Axovant believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Axovant expected. In addition, Axovant’s business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from clinical trials; the expectations for regulatory submissions and approvals; the potential safety concerns or profile of Axovant’s product candidates; and the availability or commercial potential of product candidates. These statements are also subject to a number of material risks and uncertainties that are described in Axovant’s most recent Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2018, filed with the Securities and Exchange Commission on February 7, 2019, as updated by its subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. Axovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts:

Media

Mike Beyer

Sam Brown Inc.

(312) 961-2502

Investors

Tricia Truehart

Axovant

(631) 892-7014